pogostone profile

Pogostone: volatile oil of Pogostemon cablin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Related Flora

Flora	Rank	Flora Definition	Family	Family Definition
Pogostemon	genus	Genus in the Lamiaceae family. VOLATILE OILS from several species of Pogostemon are used in PERFUME; INSECT REPELLENTS; and ALTERNATIVE THERAPIES.[MeSH]	Lamiaceae	The mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]
Pogostemon cablin	species	[no description available]	Lamiaceae	The mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]

ID Source	ID
PubMed CID	54695756
CHEBI ID	138756
SCHEMBL ID	131729
MeSH ID	M0464476

Synonym
pogostone
CHEBI:138756
dhelwangin
S9094
23800-56-8
4-hydroxy-6-methyl-3-(4-methylpentanoyl)-2-pyrone
SCHEMBL131729
2h-pyran-2-one, 4-hydroxy-6-methyl-3-(4-methyl-1-oxopentyl)-
4-hydroxy-6-methyl-3-(4-methylpentanoyl)-2h-pyran-2-one
AC-34255
AKOS028108224
AKOS026745813
4-hydroxy-6-methyl-3-(4-methyl-1-oxopentyl)-2h-pyran-2-one, 9ci
FT-0705026
4-hydroxy-6-methyl-3-(4-methyl-1-oxopentyl)-2h-pyran-2-one
HY-N1416
mfcd09837856
DTXSID001019967
6-methyl-3-(4-methylpentanoyl)-4-oxidanyl-pyran-2-one
QG8U8GA5EP ,
CCG-266750
CS-0016840
MS-23260
4-hydroxy-6-methyl-3-(4-methylpentanoyl)pyran-2-one
unii-qg8u8ga5ep

Research Excerpts

Overview

Pogostone (PO) is a major component of Pogostemon cablin. It has a variety of pharmacological properties, including antiinflammatory, and immunosuppressive activities, and antioxidant.

Excerpt	Reference	Relevance
"Pogostone (PO) is a major component of the essential oil from"	( Pogostone attenuates adipose tissue inflammation by regulating the adipocyte-macrophage crosstalk Dong, W; Li, D; Peng, C; Wang, Z; Xing, Z; Yang, C; Yu, T, 2022)	2.89
"Pogostone (PO) is a major component of Pogostemon cablin which has a variety of pharmacological properties, including antiinflammatory, and immunosuppressive activities, and antioxidant."	( Protective effect of pogostone on murine norovirus infected-RAW264.7 macrophages through inhibition of NF-κB/NLRP3-dependent pyroptosis. Chen, J; Hou, Z; Ling, Q; Shen, J; Shi, L; Yang, T; Ye, Q; Zhao, J; Zhou, H, 2021)	1.66
"Pogostone is an important constituent of Pogostemon cablin (Blanco) Benth., and possesses various known bioactivities. "	( LC-MS/MS determination of pogostone in rat plasma and its application in pharmacokinetic studies. Chen, H; Chen, J; Lai, X; Li, C; Li, Q; Li, Y; Qin, Z; Su, Z; Wu, X; Yi, Y, 2013)	2.13
"Pogostone is an important constituent of Pogostemon cablin, and possesses various bioactivitys."	( Pogostone induces autophagy and apoptosis involving PI3K/Akt/mTOR axis in human colorectal carcinoma HCT116 cells. Cao, ZX; Huang, J; Lei, S; Li, YZ; Peng, C; Wang, WW; Xie, XF; Xiong, L; Yang, YT; Yu, S, 2017)	2.62

Actions

Excerpt	Reference	Relevance
"Pogostone does not inhibit the expression of MCR-1."	( Pogostone Enhances the Antibacterial Activity of Colistin against MCR-1-Positive Bacteria by Inhibiting the Biological Function of MCR-1. Deng, X; Fang, T; Li, L; Shen, X; Tan, W; Xie, S; Zhan, B, 2022)	2.89

Treatment

Excerpt	Reference	Relevance
"Pogostone pretreatment significantly raised the depressed activities of superoxide dismutase, glutathione and catalase, while reduced the elevated malonaldehyde level compared with indomethacin-induced group."	( The gastroprotective effect of pogostone from Pogostemonis Herba against indomethacin-induced gastric ulcer in rats. Chen, HM; Chen, XY; Fu, LD; Huang, XQ; Lai, XP; Liang, YZ; Liu, YH; Su, ZQ; Su, ZR; Xie, JH; Zhang, X; Zhang, ZB; Zheng, YF, 2016)	1.44

Pharmacokinetics

The validated method was successfully applied to the preclinical pharmacokinetic investigation of pogostone in rats after intravenous (5, 10 and 20 mg/kg) and oral administration.

Excerpt	Reference	Relevance
" The validated method was successfully applied to the preclinical pharmacokinetic investigation of pogostone in rats after intravenous (5, 10 and 20 mg/kg) and oral administration (5, 10 and 20 mg/kg)."	( LC-MS/MS determination of pogostone in rat plasma and its application in pharmacokinetic studies. Chen, H; Chen, J; Lai, X; Li, C; Li, Q; Li, Y; Qin, Z; Su, Z; Wu, X; Yi, Y, 2013)	0.91
" The method was successfully applied to a pharmacokinetic study after the oral administration of pogostone to beagle dogs."	( A gas chromatography-mass spectrometry method for the determination of pogostone in canine plasma and its application to a pharmacokinetic study. Gong, X; Li, Y; Peng, C; Xiong, L; Zhang, R, )	0.58

Bioavailability

Excerpt	Reference	Relevance
" Finally, the oral absolute bioavailability of pogostone in rats was calculated to be 70."	( LC-MS/MS determination of pogostone in rat plasma and its application in pharmacokinetic studies. Chen, H; Chen, J; Lai, X; Li, C; Li, Q; Li, Y; Qin, Z; Su, Z; Wu, X; Yi, Y, 2013)	0.95

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Class	Description
aromatic ketone	A ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (13.89)	29.6817
2010's	25 (69.44)	24.3611
2020's	6 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (7.89%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	35 (92.11%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
4-aminopyridine [no description available]	2.15	1	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	7.13	1	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	7.41	1	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
chrysophanic acid chrysophanic acid: RN given refers to parent cpd; structure in Merck, 9th ed, #2260. chrysophanol : A trihydroxyanthraquinone that is chrysazin with a methyl substituent at C-3. It has been isolated from Aloe vera and exhibits antiviral and anti-inflammatory activity.	2.08	1	dihydroxyanthraquinone	anti-inflammatory agent; antiviral agent; plant metabolite
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	3.91	3	dialdehyde	biomarker
4-dimethylaminopyridine 4-dimethylaminopyridine: catalyst for acetylation of hydroxy cpds; structure	2.15	1	dialkylarylamine; tertiary amino compound
patchouli alcohol patchouli alcohol: major component of the essential oil of patchouli; perfumery raw material. patchouli alcohol : A carbotricyclic compound and sesquiterpenoid tertiary alcohol that is tricyclo[5.3.1.0(3,8)]undecan-3-ol which is substituted at positions 2, 2, 6 and 8 by methyl groups (the 1R,3R,6S,7S,8S-diastereoisomer).	4.65	8
seychellene seychellene: from the essential oil of Indian valerian (Valeriana jatamansi); structure in first source	3.21	1
spathulenol spathulenol: sesquiterpene alcohol isolated from essential oils of Artemisia vulgaris L. & Artemisia dracunculus L.. spathulenol : A tricyclic sesquiterpenoid that is 4-methylidenedecahydro-1H-cyclopropa[e]azulene carrying three methyl substituents at positions 1, 1 and 7 as well as a hydroxy substituent at position 7.	2.07	1
sesquiterpenes [no description available]	4.76	9
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.11	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
calamenene calamenene: from the New Zealand Liverwort Lepidolaena hodgsoniae; structure in first source	2.07	1
alpha-bulnesene alpha-bulnesene: platelet-activating factor receptor antagonist from Pogostemon cablin; structure in first source	3.21	1
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.13	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
colistin Colistin: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.. colistin : A multi-component mixture comprising mostly of colistin A (R = Me) and B (R = H), with small amounts of colistin C and other polymyxins, produced by certain strains of Bacillus polymyxa var. colistinus. An antibiotic, it is used as its sulfate salt (for oral or topical use) or as the sodium salt of the N-methylsulfonic acid derivative (the injectable form) in the treatment of severe Gram-negative infections, partiularly those due to Pseudomonas aeruginosa.	7.41	1
4-hydroxy-6-methyl-2-pyrone 4-hydroxy-6-methyl-2-pyrone: structure in first source	2.15	1	2-pyranones

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.41	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.41	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.41	1
Bone Loss, Osteoclastic [description not available]	2.6	1
Breast Cancer [description not available]	7.6	1
Osteolysis Dissolution of bone that particularly involves the removal or loss of calcium.	7.6	1
Age-Related Osteoporosis [description not available]	2.6	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.6	1
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	2.6	1
Caliciviridae Infections Virus diseases caused by CALICIVIRIDAE. They include HEPATITIS E; VESICULAR EXANTHEMA OF SWINE; acute respiratory infections in felines, rabbit hemorrhagic disease, and some cases of gastroenteritis in humans.	2.31	1
Gastroenteritis INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.	2.31	1
E coli Infections [description not available]	2.52	2
Infections, Staphylococcal [description not available]	2.83	3
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	2.52	2
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	2.83	3
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.08	1
Endotoxin Shock [description not available]	2.1	1
Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.	2.1	1
Gastric Ulcer [description not available]	2.52	2
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	2.52	2
Delayed Hypersensitivity [description not available]	2.11	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.5	2
Lung Injury, Acute [description not available]	2.13	1
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	7.13	1
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	3.04	1
Skin Aging The process of aging due to changes in the structure and elasticity of the skin over time. It may be a part of physiological aging or it may be due to the effects of ultraviolet radiation, usually through exposure to sunlight.	3.04	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	7.13	1
Colorectal Cancer [description not available]	2.15	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.15	1
Candida Infection [description not available]	2.07	1
Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)	2.07	1

pogostone

Description

Cross-References

Synonyms (25)

Research Excerpts

Overview

Actions

Treatment

Pharmacokinetics

Bioavailability

Drug Classes (1)

Research

Studies (36)

Market Indicators

Research Demand Index: 27.25

Study Types

pogostone

Description

Related Flora

Cross-References

Synonyms (25)

Research Excerpts

Overview

Actions

Treatment

Pharmacokinetics

Bioavailability

Drug Classes (1)

Research

Studies (36)

Market Indicators

Research Demand Index: 27.25

Study Types

Related Drugs (16)

Related Conditions (31)